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Minimally invasive surgery is increasing attention worldwide as an effective treatment 
approach in gastric cancer. 
In this context, several studies suggest that robotic technology may add some advantages 
over traditional laparoscopy, but the role of the robotic approach in the common surgical 
setting is still uncertain. 
The objective of this study is to review the current evidences in the literature comparing 
robotic surgery to other surgical approaches.
Patients underwent robotic gastrectomy showed some benefits in terms of blood loss, 
postoperative morbidity, and length of hospital stay. No significant differences have 
been found in terms of survivals, while the number of lymph nodes retrieved with the 
robotic approach, expecially in the extraperigastric region, is generally higher than that 
of laparoscopy.
The current studies in the literature suggest that the robotic gastrectomy is not inferior to 
the laparoscopic procedure and provides some surgical and clinical benefits.
Keywords:
gastric cancer; robotic gastrectomy; minimally invasive surgery.
© The Author(s) 2021. Published by ED Marketing & Communication. All rights reserved.
www.journalofgastricsurgery.comDi Nardo D., et al./ JGS 3 (2021) 
doi: 10.36159/jgs.v3i2.80 
Background
Robotic surgery was born with the intention of 
overcoming the intrinsic technical limitations of the 
laparoscopic approach and of facilitating and making 
safer complex surgical maneuvers performed in 
traditional laparoscopy. In recent years, there has been a 
significant increase in the use of the robotic platform for 
the performance of gastrectomy for cancer and above all 
of total gastrectomy and extended lymphectomy (D2) in 
the treatment of advanced gastric cancer[1-3].
Performing D2 lymphectomy with removal of 
extraperigastric lymph nodes represents a technically 
demanding surgical maneuver to be performed 
laparoscopically. Along with intra-body anastomoses, 
D2 represents the limits of the application and diffusion 
of laparoscopic surgery for the treatment of gastric 
cancer[4]. These surgical steps of gastrectomy, in fact, 
require the execution of extremely delicate and fine 
surgical maneuvers that require high precision and 
excellent vision of the operating field.
Methods
Two authors (DDN, GP) performed an independent 
literature search. The PubMed/MEDLINE databases 
were queried with the following search: “robot-assisted 
surgery” and “laparoscopic” and “gastric cancer” and 
“gastrectomy”. All article types were considered
including case reports and case series. Reviews and 
meta-analyses were also included in the analysis.
The search was limited to the English language literature. 
The
two authors evaluated and selected titles and abstracts 
of the relevant records. The included articles were 
fully revised and discussed among the authors and 
differences in opinion were solved with the opinion of 
a third author (AP).
The studies met the following criteria:
• Patients undergoing robotic total or distal gastrectomy 
for gastric cancer.
• Data on perioperative, post-operative, and oncological 
outcomes.
Continuous data are shown as mean ± standard 
deviation, whereas Categorical data are reported as 
numbers and percentages.
Robotic lymphadenectomy
SThe limited ergonomics and rigidity of laparoscopic 
instruments make the execution of D2 lymphectomy 
particularly difficult to perform, even for experienced 
laparoscopic surgeons. Specifically, the lymph node 
stations that are most difficult to remove with the 
laparoscopic technique appear to be numbers 4sa, 
6, 9, 10, 11p, and 12a[5]. In addition to the technical 
complexity of the laparoscopic execution of a complete 
D2 lymphectomy (from the point of view of oncological 
principles), the technique brings with it the risk of 
iatrogenic haemorrhagic lesions of the large vessels 
along which some lymph node stations must be 
removed. These include the infrapyloric region, the 
inferior mesenteric vein (stations 6 and 14), and the 
lymph nodes of the supra-pancreatic region, including 
stations 7, 8, and 9[6].
The technical complexity of D2 lymphectomy, therefore, 
has the potential to result in the removal of a reduced 
number of lymph nodes, which in turn potentially 
implies a worsening of patient survival and an increase 
in intra-and postoperative morbidity. The guidelines 
of the U.S. National Comprehensive Cancer Network 
(NCCN) on the surgical treatment of gastric cancer not 
only indicate D2 lymphectomy as a standard curative 
treatment but also indicate the removal of at least 15 
lymph nodes in order to achieve adequate staging of the 
disease. This guideline is based on a study that suggests 
that at least 15 lymph nodes be removed as the minimum 
necessary to obtain a survival benefit for the patient and 
to obtain a correct staging of the disease[7]. This study, 
like others[8], has shown that a continuous increase in 
survival is obtained with an increase in the number of 
lymph nodes removed, up to 40.
There are studies in the literature that have shown the 
removal of a significantly lower number of lymph nodes 
in D2 lymphectomy performed with the laparoscopic 
approach compared to the open approach. In particular, 
in the study by Miura and colleagues, a reduced number 
of lymph nodes removed with the laparoscopic approach 
compared to the open approach was detected at the 
level of the lymph node stations along the great gastric 
curvature (stations 4 and 6), at the level of the celiac axis 
(station 9), and along the splenic artery (stations 11), 
resulting in an incomplete D2 lymphectomy[5]. Other 
authors found a significant reduction in the number of 
lymph nodes removed by laparoscopy compared to the 
open approach, even in the lymph node stations located 
along the common hepatic artery during laparoscopic 
distal gastrectomy[9]. 
Another surgical maneuver that is particularly 
difficult to perform laparoscopically in the context of 
D2 lymphectomy is that required when, based on the 
location of the neoplasm along the great gastric curve, 
it is necessary to remove the lymph nodes of the splenic 
hilum (station 10) to avoid the removal of the spleen 
and pancreatic tail. The removal of this organ and 
partial organ has been shown to have the potential to 
significantly increase perioperative morbidity and 
reduce survival[10, 11]. The lymph node dissection of 
the splenic hilum (station 10), with preservation of the 
spleen, is, in fact, particularly complex due to the depth 
inside the abdomen of the location of the splenic hilum 
and the wide anatomical variability of the terminal 
branches of the splenic artery along which the lymph 
nodes to be removed are located[12]. In this case, 
the possibility of causing uncontrollable bleeding or 
damage to the pancreas or spleen is very high, especially 
when using rigid and poorly ergonomic laparoscopic 
instruments.
The technical advantages offered by the robotic platform 
compared to laparoscopy are particularly important in 
oncological gastric surgery. In fact, the robotic approach 
makes it possible to perform lymph node dissection 
with greater precision and safety of the stations most 
difficult to remove laparoscopically, also reducing the 
risk of bleeding and iatrogenic damage to organs[13]. 
Robots can accomplish this because their articulated 
instruments make it is possible to perform finer and 
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more delicate surgical maneuvers that avoid tractions 
and excessive pressure on the tissues. Robots perform a 
more precise dissection compared to their laparoscopic 
counterparts, giving them the potential to reduce blood 
loss and to reduce trauma to organs and tissues[14].
The use of the robot also allows the elimination of the 
physiological tremor of the operator as well as that 
of the laparoscopic instruments, resulting in high-
definition three-dimensional images of the operating 
field taken by robotic video-optics. Moreover, because 
robotic instruments are articulated, and being provided 
with “endowrist” (which allows the tip of the robotic 
instruments to rotate like the human wrist), they also 
allow for increased dexterity of movements inside the 
abdomen.
These features make it easier to carry out complete lymph 
node dissections even in areas that are difficult to access 
and “uncomfortable” to reach with rigid laparoscopic 
instruments. These areas include the region of the 
splenic hilum and the dorsal region of the pancreas, 
along which lies part of the D2 lymphectomy[13]. In 
fact, using laparoscopic instruments, it is difficult to 
reach this superior-posterior part of the pancreatic back, 
on which the splenic artery and the relative lymph node 
stations run, without applying excessive pressure on the 
pancreatic gland. This poses the risk of haemorrhagic 
lesions or of causing lesions of the gland with the ensuing 
onset of pancreatitis and pancreatic fistulas.
In these cases, and for all the other extra-perigastric 
lymph node stations in general, having the technical 
advantages of robotic surgery allows these surgical steps 
to be performed with greater comfort, precision, and 
ease, and therefore, theoretically, with greater efficacy 
and safety than the laparoscopic approach.
Reconstruction possibilities
It should be emphasized that the potential benefits of 
using the robot in gastric cancer surgery also lie in the 
advantages that this approach offers in the execution 
of intracorporeal anastomoses. Intracorporeal intestinal 
anastomoses represent another major technical 
limitation of traditional laparoscopy due to the difficulty 
of performing intracorporeal sutures with laparoscopic 
instruments[15].
This is particularly evident after performing a total 
gastrectomy, which requires the preparation of an 
esophagus-jejunal anastomosis and a jejuno-jejunal 
anastomosis, in the case of reconstruction with a Roux-
en-Y technique. In this case, robotic surgery is particularly 
useful because of the technical advantages previously 
described. In fact, in the event that an intracorporeal 
esophagus-jejunal anastomosis is to be performed with 
a circular mechanical suturing device, as often happens 
in open surgery, the greater capacity of intracorporeal 
manipulation of the robot allows the placement and 
fixation of the head of the circular suturing device with 
greater dexterity and ease at the level of the esophageal 
stump, compared to the laparoscopic approach[13]. If an 
intracorporeal esophagus-jejunal anastomosis is planned 
with total manual suturing, the robot also offers, in this 
case, the possibility of performing sutures with greater 
ease and precision than laparoscopy, in particular in 
narrow and difficult-to-reach spaces such as the area 
of the esophageal hiatus[16, 17]. The intracorporeal 
performance of the anastomoses, facilitated by robotic 
surgery, allows us to avoid the creation of large incisions 
often necessary in laparoscopy to perform intestinal 
anastomoses. Therefore, robots allow us to respect even 
more the principles of minimal invasiveness, potentially 
increasing the rate of totally intracorporeal procedures. 
 Comparison of outcomes
The first report in the literature describing a robotic 
gastrectomy was published in 2003 by Hashizume and 
colleagues[18].
Over the last decade, many studies have confirmed 
the feasibility of the robotic approach for performing 
gastrectomies for cancer. However, while the current 
literature presents three RCTs, only one of them, 
from the Department of Gastric Surgery at Fujian 
Medical University Union Hospital (Fuzhou), headed 
by Prof. Chang-Ming Huang, uses a high-quality 
methodology[19]. 
The RCT from this high-volume Gastric Cancer Center 
evaluated the short-term outcomes of patients who 
underwent robotic distal gastrectomy and compared 
them with those patients who underwent laparoscopic 
distal gastrectomy.
This is a relevant study, because despite the increasing 
use of robotic technology in gastric cancer patients, its 
safety and efficacy have not yet been delineated in a 
randomized controlled trial. This study represents the 
first RCT in this setting.
Three hundred patients with cT1-4a and N0/+ (between 
September 2017and January 2020) were enrolled. 
The robotic group showed a faster postoperative 
recovery, milder inflammatory responses, and reduced 
postoperative morbidity (9.2% vs. 17.6%; respectively, 
p=0.039). Higher extraperigastric lymph nodes were 
retrieved in favor of the robotic group (17.6 ± 5.8 vs. 15.8 
± 6.6, p=0.018), with a lower noncompliance rate (7.7% 
vs. 16.9%; respectively, p = 0.006). Moreover, patients 
in the robotic group were more likely to start adjuvant 
chemotherapy earlier (median postoperative days: 28 
[24-32] vs. 32 [26-42], p=0.003). 
The direct cost was lower for the robotic approach 
than for laparoscopy (p<0.001). Therefore, the authors 
concluded that robotic surgery is associated with a lower 
morbidity rate, faster recovery, milder inflammatory 
responses, and improved lymphadenectomy.
In this context, another landmark study is a prospective 
study from the same Department of Gastric Surgery at 
Fujian Medical University Union Hospital (Fuzhou), 
headed by Prof. Chang-Ming Huang[20]. This compares 
the short-term outcomes, surgery burden, and 
technical performance of robotic total gastrectomy and 
laparoscopic total gastrectomy.
The study included 50 patients with advanced gastric 
cancer who underwent robotic gastrectomy combined 
with spleen-preserving splenic hilar lymphadenectomy 
between March 2018 and February 2020. 
The robotic group had a lower volume of intraoperative 
blood loss than the laparoscopy group (38.7 vs. 66.4 
mL, P = 0.042). The robotic approach also allowed the 
retrieval of more extraperigastric lymph nodes (20.2 vs. 
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17.5, P = 0.039). 
The number of errors was lower in the robotic group 
than in the laparoscopic group (43.2 vs. 53.8 times/case, 
P < 0.001). A higher technical skill score (30.2 vs. 28.4, 
P < 0.001) and a lower surgery task load index (33.2 
vs. 39.8, P <0.001) was shown in favor of the robotic 
surgery. There were no significant differences in terms 
of postoperative morbidity (14.6% vs. 16.7%, P = 0.748).
The authors of the final report on this high-level research 
concluded that robotic technology could provide 
experienced surgeons at high-volume, specialized 
institutions with a more precise operating environment 
and reduced surgical burden. 
We believe that when robotic surgery is popularized to 
a certain, the urgent high-level evidence is warranted 
for its spreading. The two studies conducted by Fujian 
Medical University Union Hospital firstly confirmed 
the better short-term efficacy of robotic gastrectomy 
than laparoscopic gastrectomy and provided high-
level evidence for the application of robotic surgery for 
patients with GC. These evidences play an important 
role in promoting the development and popularization 
of robotic gastrectomy for gastric cancer, which also 
provides more high-quality options for surgical 
treatment for patients with gastric cancer. In addition, 
these findings are of great significance to guide the 
Western surgeons to carry out minimally invasive 
gastric cancer surgery due to the low incidence rate of 
GC in Western regions.
Another study[21] compared the number of lymph 
nodes removed in 586 open, 64 laparoscopic, and 
39 robotic gastrectomies. The authors of the study 
emphasized that they have encountered technical 
difficulties in performing D2 lymphectomy with a 
laparoscopic approach and to have performed a D2 
lymphectomy only in 19% of patients treated with a 
laparoscopic approach compared to 88% of patients in 
the open group and 87% of patients in the robotic group. 
They also emphasized that with the help of robotic 
instrumentation, the execution of the D2 lymphectomy 
is considerably facilitated compared to the laparoscopic 
approach, in particular for the removal of infrapyloric 
and suprapancreatic lymph node stations[21]. 
Yoon and colleagues[22] specifically compared 
laparoscopic total gastrectomy with D2 lymphectomy 
performed in 65 patients versus a robotic procedure 
performed on a total of 36 patients. In particular, the 
authors claim that the robotic group removed a higher 
number of lymph nodes in the extraperigastric stations 
(stations 7–14) and, in particular, the suprapancreatic 
ones (stations 7–12a) in the splenic hilum and along 
the splenic artery. This suggests that robotic surgery 
actually facilitates the removal of lymph node stations 
that are more difficult to remove by laparoscopy.
Junfeng[23] found a significantly higher mean number 
of lymph nodes removed with the robotic approach 
(mean of 34.6 lymph nodes removed) compared to 
laparoscopy (mean of 32.7 lymph nodes removed). 
Specifically, the authors found a significantly higher 
number of lymph nodes removed with the robotic 
approach in the extraperigastric stations, explaining 
that this could be linked to the fact that the robotic 
approach facilitates exposure and dissection of some 
lymph node stations of the second level (such as stations 
7, 8a, 9, and 11p), whose removal is notoriously more 
complex with the laparoscopic approach. This study is 
also one of few to report data on the 3-year survival of 
the patients included in the study. The 3-year overall 
survival rates were 67.8% in the robotic group and 69.9% 
in the laparoscopic group, and, therefore, substantially 
overlapping.
The authors of the study, Son and colleagues[24], found 
no significant difference in terms of the overall number 
of lymph nodes removed (mean of 47.2 lymph nodes 
removed with the robotic approach and 42.8 with the 
laparoscopic approach), but confirmed that the robotic 
approach allowed the removal of a significantly greater 
number of lymph nodes located in notoriously difficult-
to-remove stations, such as the splenic hilum and along 
the splenic artery.
In another study, Wang and colleagues[25] compared 
the execution of robotic gastrectomy with the open 
approach. The authors randomized a total of 145 
patients to an open surgery treatment group and 151 
patients to a robotic treatment group. The results of the 
study did not reveal significant differences in terms of 
the number of lymph nodes removed between the open 
and robotic approaches (mean of 30.9 versus 29.3 lymph 
nodes removed with the open and robotic approaches, 
respectively), or in terms of postoperative complication 
rates. However, robotic surgery has made it possible 
to obtain a significant advantage in terms of reducing 
the amount of intraoperative blood loss, the length 
of hospital stay, and the time necessary for intestinal 
function to resume. The robotic approach, however, is 
burdened by significantly longer operating times than 
the open approach. 
Discussion
In sum, current studies regarding the execution 
of gastrectomy with robotic D2 lymphectomy for 
cancer report conflicting results in terms of short-
term oncological outcomes (number of lymph nodes 
removed) compared to the open and laparoscopic 
methods. Few studies have evaluated long-term 
survival (3 years) after performing a gastrectomy with 
robotic D2 lymphectomy. The number of lymph nodes 
removed is typically considered only as a surrogate 
measure of survival, which instead represents the best 
endpoint for evaluating the oncological efficacy of a 
surgical procedure. However, in the case of gastric 
cancer, numerous studies, including some so-called 
population studies, performed in both high- and low-
volume centers, show that survival improves with the 
increase in the number of lymph nodes removed[26-29]. 
It remains difficult to ascertain whether this is linked 
to a real therapeutic beneficial effect or to the so-called 
phenomenon of “stage migration” [30].
In this regard, as already pointed out, there are currently 
few studies in the literature that have described survival 
after gastrectomy with robotic D2 lymphectomy 
compared to the laparoscopic counterpart, and no 
study has performed a comparison, in terms of survival, 
between robotic and open approaches.
A study by Li and colleagues[31] included patient 
survival at follow-up among the endpoints. The 
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researchers compared 112 patients who underwent 
robotic gastrectomy versus 112 patients who underwent 
laparoscopic gastrectomy with D2 lymphectomy. The 
authors found no significant difference in terms of the 
number of lymph nodes removed between the two 
groups or in terms of 3-year overall survival (78.6% 
vs 74.1% respectively in the robotic and laparoscopic 
groups). Eighteen percent of the robotic group and 21% 
of the laparoscopic group had a recurrence of disease at 
the 3-year follow-up. 
The oncological follow-up of two groups of patients 
undergoing robotic or laparoscopic gastrectomy was 
also analyzed in a retrospective observational study by 
Pugliese and colleagues[32]. However, in this study, 
there are a number of patients in both groups (about 
half) affected by early gastric cancer and therefore 
not subjected to D2 lymphectomy. The robotic group 
had a follow-up of only 28 months, and therefore, 
only the three-year survival was reported, which is 
not significantly different between the two groups of 
patients (85% versus 78% in the robotic and laparoscopic 
groups, respectively).
Junfeng and colleagues[23] compared 120 robotic versus 
394 laparoscopic gastrectomies and found no significant 
difference in terms of 3-year survival between the two 
groups (the robotic group and the laparoscopic group had 
1-year survival rates of 90.2% and 78.1, respectively). % 
at 2 years and 67.8% at 3 years, while in the laparoscopic 
group 87.3% at 1 year, 77.1% at 2 years and 69.9% at 3 
years). In this study, however, a significant proportion 
of patients underwent D1 lymphectomy.
Finally, the study by Son and colleagues[24] currently 
reports the longest follow-up after robotic gastrectomy, 
with an average follow-up duration of 70 months. 
From the comparison between robotic and laparoscopic 
gastrectomy with D2 lymphectomy, the authors found 
no statistically significant difference either in terms 
of 5-year overall survival (89.5% in the robotic group 
versus 91.1% in the laparoscopic group) or in terms of 
disease-free survival (90.2% in the robotic group versus 
91.2% in the laparoscopic group).
Ultimately, analyzing the literature available to date, 
it is impossible not to see the growing attention of the 
international scientific community with respect to the 
use of both laparoscopic and robotic minimally invasive 
surgical techniques for the treatment of gastric cancer 
due to their ability to produce better perioperative 
outcomes compared to surgery. Open (including pain 
relief, faster postoperative functional recovery, and 
reduced hospital stay). However, with regard to the 
use of the laparoscopic approach in the execution of 
D2 lymphectomy during gastrectomy for cancer, as 
mentioned, a substantially skeptical attitude of the 
international community currently persists, linked to the 
scarcity and controversy of the evidence available in the 
literature that does not make it possible to definitively 
sanction its non-inferiority in terms of oncological 
outcomes and survival rates compared to traditional 
open surgery[33]. In this scenario, the robotic system 
offers technical advantages that make the execution of 
technically more complex surgical maneuvers, such as 
D2 lymphectomy, easier and safer to perform than the 
laparoscopic counterpart. 
Despite this, the evidence supporting the superiority 
of the robotic approach over the laparoscopic approach 
in gastrectomy with D2 lymphectomy is scarce and 
contradictory, as previously emphasized and reiterated 
by many authors and by the absence at the moment 
of guidelines that regulate its use[14, 34]. As evidence 
of this, almost all studies published in the field of 
laparoscopic and robotic surgery for the treatment of 
advanced gastric cancer, or concerning the execution 
of a D2 lymphectomy, call for the conduct of new 
multicenter randomized studies on this specific topic. 
However, this type of study is notoriously difficult to 
carry out due to the high costs and the fact that not all 
centers are able to offer patients both the laparoscopic 
and robotic approaches. Moreover, in many Asian 
countries, in which the incidence of gastric cancer is 
higher, it is the patient himself who decides whether or 
not to carry out the intervention with a robotic approach 
since he has to pay for the use of robotic technology, 
making randomization impossible.
An ideal study to investigate the role of minimally 
invasive surgery in gastrectomy with D2 lymphectomy 
requires not only many patients to obtain adequate 
statistical power but also to be able to investigate many 
clinical, surgical, and oncological variables, which could 
affect the results. From this perspective, despite a large 
multicenter randomized study, the creation and use of a 
multicenter registry, like that of our international study 
group on Minimally Invasive Surgery for Gastric Cancer 
(IMIGASTRIC), represents a valid alternative tool for the 
collection and analysis of data deriving from multiple 
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